Implementing digital pathology: qualitative and financial insights from eight leading European laboratories DOI Creative Commons
Xavier Matías‐Guiu, Jordi Temprana‐Salvador, Pedro Carríón López

et al.

Virchows Archiv, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Abstract Digital Pathology (DP) revolutionizes the diagnostic workflow. Digitized scanned slides enhance operational efficiency by facilitating remote access, slide storage, reporting and automated AI image analysis, enabling collaboration research. However, substantial upfront maintenance costs remain significant barriers to adoption. This study evaluates DP’s financial qualitative value, exploring whether long-term benefits justify investments addressing implementation challenges in large public private European laboratory settings. A targeted literature review, semi-structured interviews, surveys, a net present value (NPV) model were employed assess impact on clinical practice financials. Qualitative findings validate key of DP, including optimized workflow, enhanced logistics, improved organization. Pathologists reported smooth integration, training, teaching, research capabilities, increased flexibility through work. Collaboration within multidisciplinary teams was strengthened, while case examination access archival notably improved. Quantitative results indicate that DP demonstrates strong potential, achieving cost recovery 6 years. investment 7-year NPV + €0.21 million (m) driven productivity diagnosis volumes. Although high for scanners, system integration pose barrier adoption larger institutions are better positioned leverage economies scale. underscores importance sustained support cope with initial regional driving widespread DP. Expanding reimbursement policies pathology procedures could significantly reduce barriers.

Language: Английский

Management of nausea and vomiting induced by antibody–drug conjugates DOI Creative Commons

Jawhara Farhat,

Hitomi Sakai, Junji Tsurutani

et al.

Breast Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

Citations

1
Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs DOI Creative Commons
Yizhi Jiang, Haiting Zhou, Junxia Liu

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(5), P. 652 - 652

Published: May 17, 2024

Precise targeting has become the main direction of anti-cancer drug development. Trophoblast cell surface antigen 2 (Trop-2) is highly expressed in different solid tumors but rarely normal tissues, rendering it an attractive target. Trop-2-targeted antibody-drug conjugates (ADCs) have displayed promising efficacy treating diverse tumors, especially breast cancer and urothelial carcinoma. However, their clinical application still limited by insufficient efficacy, excessive toxicity, lack biological markers related to effectiveness. This review summarizes trials combination therapy strategies for ADCs, discusses current challenges, provides new insights future advancements.

Language: Английский

Citations

8
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies DOI Creative Commons
Jun He,

Xianghua Zeng,

Chunmei Wang

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(8)

Published: July 28, 2024

Abstract Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells and cytotoxic drugs linked through linkers. By leveraging antibodies’ targeting properties, ADCs deliver into via endocytosis after identifying the antigen. This precise method aims to kill selectively while minimizing harm normal cells, offering safe effective therapeutic benefits. Recent years have seen significant progress in antitumor treatment with ADC development, providing patients new potent options. With over 300 explored for various indications some already approved clinical use, challenges such as resistance due factors like antigen expression, processing, payload emerged. review outline history their structure, mechanism action, recent composition advancements, selection, completed ongoing trials, mechanisms, intervention strategies. Additionally, it will delve potential novel markers, linkers, payloads, innovative action mechanisms enhance cancer The evolution has also led emergence combination therapy a approach improve drug efficacy.

Language: Английский

Citations

7
Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy DOI Creative Commons
Antonio Pinto, Chiara Guarini,

Marianna Giampaglia

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(9), P. 1146 - 1146

Published: Aug. 29, 2024

The advent of immunotherapy and antibody–drug conjugates (ADCs) have revolutionized breast cancer treatment, offering new hope to patients. However, challenges, such as resistance limited efficacy in certain cases, remain. Recently, the combination these therapies has emerged a promising approach address challenges. ADCs play crucial role by delivering cytotoxic agents directly cells, minimizing damage healthy tissue enhancing tumor-killing effect. Concurrently, immunotherapies harness body’s immune system recognize eliminate cells. This integration offers potential overcome mechanisms significantly improve therapeutic outcomes. review explores rationale behind combining with ADCs, recent advances this field, implications for treatment.

Language: Английский

Citations

7
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents DOI
Margherita Gobbo,

Jamie K. Joy,

Helena Guedes

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(6), P. 727 - 742

Published: April 12, 2024

The introduction of targeted therapy and immunotherapy has tremendously changed the clinical outcomes prognosis cancer patients. Despite innovative pharmacological therapies improved radiotherapy (RT) techniques, patients continue to suffer from side effects, which oral mucositis (OM) is still most impactful, especially for quality life. We provide an overview current advances in pharmacotherapy RT, relation their potential cause OM, less explored more recent literature reports related best management OM. have analyzed natural/antioxidant agents, probiotics, mucosal protectants healing coadjuvants, pharmacotherapies, immunomodulatory anticancer photobiomodulation impact technology. discovery precise pathophysiologic mechanisms CT RT-induced OM outlined that a multifactorial origin, including direct oxidative damage, upregulation immunologic factors, effects on flora. A persistent upregulated immune response, associated with factors patients' characteristics, may contribute severe long-lasting goal strategies conjugate individual patient, disease, therapy-related guide prevention or treatment. further high-quality research warranted, issue paramount future strategies.

Language: Английский

Citations

5
Trophoblast cell surface antigen‐2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma DOI Creative Commons
Richard Weiten, Enno Storz,

Carolina Kessler

et al.

BJU International, Journal Year: 2024, Volume and Issue: 134(4), P. 615 - 621

Published: June 19, 2024

Objective To evaluate the potential utility of antibody‐drug conjugates targeting trophoblast cell surface antigen‐2 (TROP‐2) in patients with primary penile squamous carcinoma (PSCC), recurrence (REC cohort), and patient‐matched distant metastases (MET to assess use TROP‐2 as a predictive non‐invasive biomarker PSCC. Methods A cohort comprising PRIM ( n = 37), REC 5) MET subcohort 7), including lymph node lung metastases, was analysed using quantitative real‐time PCR, ELISA immunohistochemical staining evaluation H‐score. Results mRNA serum protein levels were significantly increased recurrent PSCC compared cancer‐free controls (both P < 0.001). Immunohistochemical analysis revealed that most 34/37, median H‐score 260, interquartile range [IQR] 210–300), well all (median 200 [165–290]) cohorts 280 [260–300]) exhibited moderate strong membranous expression. Additionally, The (membranous expression) positively correlated ρ 0.69, 0.0001, R 2 0.70) 0.86, 0.59), indicating its Conclusion In summary, our results support further studies on diagnostic therapeutic target primary, metastatic

Language: Английский

Citations

5
The clinical landscape of antibody-drug conjugates in endometrial cancer DOI
Giovanni Fucá, Ilaria Sabatucci,

Mariachiara Paderno

et al.

International Journal of Gynecological Cancer, Journal Year: 2024, Volume and Issue: 34(11), P. 1795 - 1804

Published: July 29, 2024

Clinical outcomes remain challenging in advanced or recurrent endometrial cancer due to tumor heterogeneity and therapy resistance. Antibody-drug conjugates are a novel class of therapeutics, representing promising treatment option for cancer. consist high-affinity antibody linked cytotoxic payload through stable linker. After binding specific antigens on cells, the drug is internalized, released. In addition, free intracellular may be released outside target cell 'bystander effect' kill neighboring which crucial treating malignancies characterized by heterogeneous biomarker expression like This article aims provide comprehensive overview current clinical landscape antibody-drug We conducted thorough analysis recent trials focusing efficacy, safety profiles, mechanisms focused particularly most conjugate targets under investigation, such as human epidermal growth factor receptor 2 (HER2), folate alpha (FRα), trophoblast cell-surface antigen-2 (TROP2), B7-H4. also briefly comment challenges, including emergence resistance mechanisms, future development directions (especially agents targeting multiple antigens, combinatorial strategies, sequential use same antigen but using different payloads)

Language: Английский

Citations

5
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker DOI Creative Commons
Shiqin Liu,

Sarah Hawley,

Christian A. Kunder

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Jan. 4, 2024

Abstract Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences decision-making between treatment active surveillance. The development of novel predictive biomarkers will help with risk stratification, decision-making, leading to decrease in over or under-treatment patients cancer. Here, we report that Trop2 prognostic tissue biomarker for by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed 1100 multi-institutional study. We demonstrate elevated expression correlated worse features including Gleason score, age, pre-operative PSA levels. More importantly, at radical prostatectomy predicts overall survival men undergoing prostatectomy. Additionally, detect shed urine Our study identifies as candidate non-invasive marker

Language: Английский

Citations

4
Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development DOI
Qi Ma,

Puro Durga,

Frederick X.C. Wang

et al.

Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(8), P. 104057 - 104057

Published: June 5, 2024

Language: Английский

Citations

4
Targeting Trop-2 as a Cancer Driver DOI
Emanuela Guerra, Marco Trerotola, Saverio Alberti

et al.

Journal of Clinical Oncology, Journal Year: 2023, Volume and Issue: 41(29), P. 4688 - 4692

Published: Aug. 7, 2023

Article Tools UNDERSTANDING THE PATHWAY OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01. June 16, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01207 Journal Clinical Oncology - published online before print August 7, PMID: 37549340 Targeting Trop-2 as a Cancer Driver Emanuela Guerra , PhD1,2xEmanuela GuerraSearch for articles by this author; Marco Trerotola PhD1,2xMarco TrerotolaSearch Saverio Alberti MD, PhD3xSaverio AlbertiSearch author Show More 1Laboratory Pathology, Center Advanced Studies Technology (CAST), G. d'Annunzio University Chieti-Pescara, Chieti, Italy2Department Medical, Oral Biotechnological Sciences, Italy3Unit Medical Genetics, Department Biomedical Sciences—BIOMORF, Messina, Italy https://doi.org/10.1200/JCO.23.01207 First Page Full Text PDF Figures Tables © American Society OncologyAUTHOR CONTRIBUTIONSConception design: All authorsCollection assembly data: authorsData analysis interpretation: Guerra, AlbertiManuscript writing: authorsFinal approval manuscript: authorsAccountable all aspects the work: authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS INTERESTTargeting DriverThe following represents disclosure information provided authors manuscript. relationships are considered compensated unless otherwise noted. Relationships self-held = Immediate Family Member, Inst My Institution. may not relate to subject matter For more about ASCO's conflict interest policy, please refer www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is public database containing reported companies payments made US-licensed physicians (Open Payments).Emanuela GuerraStock Other Ownership Interests: Mediterranea Theranostic SrlResearch Funding: SrlPatents, Royalties, Intellectual Property: Inventor patents WO2016087651 WO2017084763,Saverio AlbertiLeadership: Oncoxx BiotechStock BiotechResearch BiotechPatents, novel anti-cancer drugs companion diagnosticsTravel, Accommodations, Expenses: BiotechNo other potential conflicts were reported. Companion TROPION-PanTumor01

Language: Английский

Citations

10